In the past, many tumor marker laboratory tests have not been sensitive enough for the very early detection of cancer. However, many of them have nonetheless proved useful in monitoring therapy, following the course of the tumor, and predicting prog- nosis. Today, cancer may be viewed as a genetic disease with various specific chromo- somal and nucleotide aberrations, such as mutations, deletions, gene amplification, gene rearrangements, and translocations occurring during the transformation of a nor- mal cell into a malignant cell. The considerable advances in technology during the past several years have greatly enhanced our ability to detect human cancers in the very early stages of tumor forma- tion. These technologies include: (1) nucleotide molecular assays (genomics); (2) proteomics (multiplex protein measurements); (3) DNA microarrays; and (4) bio- informatics. Many of these technologies are already helping in the integration and use of multiple biomarkers for tumors. Although the individual biomarkers may reveal only limited information, the use of multiple biomarkers can help markedly elevate the diagnostic capabilities for early detection of tumors.

From the Back Cover

Advances in diagnostic technology during the past several years have significantly enhanced our ability to detect human cancers in the very early stages of tumor formation. In Cancer Diagnostics: Current and Future Trends, high-profile laboratory scientists and basic cancer researchers review those recent and emerging clinical laboratory tests that can help in the early detection, evaluation, and prediction of human tumors, and so permit more informed therapeutic decisions. Emphasizing the importance of molecular and genetic RNA/DNA tests that can detect persons at high risk for specific cancers, the authors explore these novel serological assays, cellular assays useful for anatomic pathology, and molecular and genetic assays. Highlights include a profile of genetic tests for the diagnosis of colon, lung, and pancreatic cancers and a discussion of the molecular microsatellite instability that is observed in many cancers and permits the diagnosis of particular cancers.
Informative and state-of-the-art, Cancer Diagnostics: Current and Future Trends thoroughly treats the best current methods for cancer diagnosis and monitoring, and points to a future in which early diagnosis and detection of cancer will become a reality.

"About this title" may belong to another edition of this title.

Store Description

Visit Seller's Storefront

Seller's business information

Edward Bowditch Ltd
Exstowe, Exton, Exeter, EX3 0PP, United Kingdom

Sale & Shipping Terms

Terms of Sale

Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch

Shipping Terms

Orders usually dispatched within two working days. Please note that at this time all domestic United Kingdom orders are sent by trackable UPS courier, we choose not to offer a lower cost alternative.

Shipping rates from United Kingdom to U.S.A.

Shipping rates from United Kingdom to U.S.A.
Order quantity	7 to 14 business days	2 to 3 business days
First item	US$ 19.64	US$ 19.64

Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.